April 23, 2025
TOPLINE: Higher variability in the levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides was independently associated with an increased risk […]
April 21, 2025
New data documented dramatic shifts in prescribing for both type 2 diabetes (T2D) and weight loss, particularly with the uptake of tirzepatide (Lilly) and declines in […]
April 18, 2025
Obesity has historically been regarded as a moral failing, and people with obesity describe being seen as deficient, lazy, and/or undeserving of respect, lacking willpower and […]
April 18, 2025
Orforglipron, Eli Lilly’s investigational oral glucagon-like peptide 1 receptor agonist (GLP-1 RA), achieved positive phase 3 results for both A1c and weight loss, according to top-line […]
April 18, 2025
The US Food and Drug Administration (FDA) has approved a new indication for osilodrostat (Isturisa, Recordati) as second-line treatment of endogenous hypercortisolemia in adults with Cushing […]
April 17, 2025
TOPLINE: Exposure to certain food additive mixtures was associated with a higher incidence of type 2 diabetes (T2D), with two specific mixtures containing emulsifiers, preservatives, and […]
April 17, 2025
In contrast to World Health Organization (WHO) guideline, a newly published report from the UK’s Scientific Advisory Committee on Nutrition (SACN) states that non-sugar sweeteners (NSS) […]
April 17, 2025
(Reuters) -Eli Lilly’s experimental pill led to weight loss of nearly 8% at the highest dose and lowered blood sugar in patients with type 2 diabetes […]
April 17, 2025
(Reuters) -Eli Lilly’s experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the […]